Vulvar Disorders

Last updated 1 Jun 2026 · Women's Health / Dermatology

📋 Key Information Summary

📋

Vulvar disorders are common yet under-diagnosed — an estimated 10–15% of Australian women will present to primary care with vulvar symptoms during their lifetime; a structured diagnostic approach is essential.
Lichen sclerosus (LS) is the most important chronic vulvar dermatosis; lifelong treatment with ultra-potent topical corticosteroids (clobetasol propionate 0.05%) reduces symptom burden and lowers the 4–5% risk of vulvar squamous cell carcinoma (SCC).
Lichen planus (LP) of the vulva may cause erosive scarring, vaginal stenosis, and significant pain; it requires specialist dermatology or gynaecology input and a combination of topical corticosteroids and calcineurin inhibitors.
Vulvar intraepithelial neoplasia (VIN) has two distinct subtypes — usual-type (HPV-related, younger women) and differentiated-type (lichen sclerosus-related, older women). All suspected VIN requires biopsy and specialist referral.
Vulvovaginal candidiasis (VVC) affects approximately 75% of women at least once; fluconazole 150 mg orally as a single dose is first-line for uncomplicated episodes. Recurrent VVC (≥4 episodes/year) requires induction and maintenance therapy.
Pruritus vulvae is a symptom, not a diagnosis — always seek an underlying cause. Common aetiologies include candidiasis, LS, contact dermatitis, and lichen simplex chronicus.
Provoked vestibulodynia (PVD) is the most common cause of provoked dyspareunia in premenopausal women. Multimodal management (pelvic floor physiotherapy, topical agents, psychological support) is more effective than pharmacotherapy alone.
The Vulvar Discomfort Diagnostic Model uses a systematic history and examination algorithm to differentiate dermatological, infectious, neoplastic, and pain-syndrome aetiologies.
Biopsy any persistent, non-responsive, or suspicious vulvar lesion — delay in biopsy is the most common reason for delayed diagnosis of vulvar malignancy in Australia.
Topical oestrogen is effective for vulvar atrophy in postmenopausal women and should be considered as adjunctive therapy in any inflammatory vulvar condition in this population.
Aboriginal and Torres Strait Islander women face higher rates of vulvar morbidity due to delayed access to specialist care, cultural barriers to examination, and higher background rates of chronic skin conditions in remote communities.
Long-term surveillance is mandatory for LS (at least annually) and VIN (per specialist protocol) given the persistent risk of malignant transformation.

Introduction & Australian Epidemiology

Vulvar disorders encompass a broad spectrum of dermatological, infectious, neoplastic, and functional conditions affecting the external female genitalia. Despite their high prevalence, vulvar conditions remain under-recognised in Australian primary care, with a median diagnostic delay of 2–5 years reported for conditions such as lichen sclerosus and provoked vestibulodynia. GPs are often the first point of contact and play a pivotal role in early diagnosis, initiation of treatment, and appropriate referral.

The vulvar skin differs from other cutaneous sites in several important ways: it is occluded, moisture-rich, subject to friction, and influenced by hormonal fluctuations. These features make it vulnerable to unique patterns of dermatoses, infections, and neoplastic change. Vulvar symptoms — pruritus, burning, pain, dyspareunia, and visible skin change — frequently overlap between conditions, making a structured diagnostic approach essential.

Australian Epidemiology

Lichen sclerosus: Prevalence estimated at 1.7% of women overall, with peak incidence in postmenopausal women (up to 3% in women >50 years). There is also a bimodal peak in prepubertal girls. Australian registry data suggest it accounts for 15–20% of vulvar dermatology referrals.
Lichen planus: Less common than LS; erosive LP affects an estimated 1–2% of women referred to vulvar clinics. Often underdiagnosed due to overlap with other erosive conditions.
Vulvar intraepithelial neoplasia: The incidence of usual-type VIN has increased over the past two decades, paralleling HPV prevalence, particularly in women aged 25–45 years. Differentiated-type VIN is associated with chronic LS and occurs predominantly in postmenopausal women.
Vulvovaginal candidiasis: Approximately 75% of Australian women experience at least one episode; 5–8% develop recurrent VVC (≥4 episodes/year). Candida albicans accounts for 85–90% of isolates; non-albicans species (predominantly C. glabrata) are increasingly recognised in recurrent and treatment-resistant cases.
Provoked vestibulodynia: Affects approximately 8–15% of Australian women at some point in their lives, making it the most common cause of provoked dyspareunia. Mean age of onset is in the mid-20s.
Vulvar cancer: Australia reports approximately 400–450 new cases annually (AIHW data), with a median age at diagnosis of 70 years. Squamous cell carcinoma accounts for >90% of cases; chronic LS is a recognised precursor in 30–50% of cases.

⚠️

Diagnostic delay harms patients. The RACGP and the Australasian Vulvovaginal Society recommend that any vulvar symptom persisting beyond 4–6 weeks, or any visible lesion not resolving with empirical treatment, warrants direct visualisation, appropriate investigation, and consideration of biopsy.

Vulvar Discomfort Diagnostic Model

The Vulvar Discomfort Diagnostic Model is a systematic, stepwise framework used in Australian primary care and vulvar clinics to categorise vulvar symptoms into four broad aetiological domains: dermatological, infectious, neoplastic, and functional/pain-related. By matching clinical features to one or more domains, clinicians can narrow differential diagnoses, guide investigations, and direct appropriate treatment or referral.

Stepwise Diagnostic Approach

Comprehensive History

Characterise the symptom (pruritus, burning, pain, dyspareunia, visible change). Document onset, duration, cyclicity (menstrual, hormonal), aggravating/relieving factors, prior treatments, sexual history, and impact on quality of life. Ask specifically about skin changes, discharge, and bleeding.

Directed Vulvar Examination

Perform under good lighting with patient in lithotomy. Systematically inspect mons pubis, labia majora, labia minora, clitoral hood, interlabial sulci, vestibule, perineum, and perianal skin. Use the "clock-face" description for lesion localisation. Note colour (white, red, pigmented), texture (atrophic, thickened, eroded), architecture (fused labia minora, loss of anatomy), and any palpable lesions.

Cotton-Swab Testing (Q-tip Test)

Essential for evaluating provoked pain. Lightly touch the vestibule at 1, 4, 6, 8, and 11 o'clock positions. Positive test (pain score ≥4/10 on NRS at one or more sites) localises the source of pain to the vestibule and supports a diagnosis of provoked vestibulodynia.

Classify into Diagnostic Domain(s)

Use findings to assign the presentation to one or more domains — dermatological (white/red/pigmented changes, scarring), infectious (discharge, acute onset, satellite lesions), neoplastic (persistent lesion, ulceration, induration), or functional/pain (normal appearance with provoked pain, hypertonic pelvic floor).

Investigate & Treat or Refer

Perform swabs (vulvovaginal, viral), skin biopsy if indicated, and arrange appropriate treatment. Refer to gynaecology, dermatology, or vulvar specialist clinic when biopsy is required, diagnosis is uncertain, or treatment has failed after 4–6 weeks.

Domain Classification Guide

Domain	Key Clinical Features	Common Diagnoses	First Action
Dermatological	White plaques, erythema, scarring, loss of architecture, erosions, desquamation	Lichen sclerosus, lichen planus, contact dermatitis, psoriasis, lichen simplex chronicus	Biopsy if persistent >6 weeks; empirical potent TCS if classic LS
Infectious	Acute onset, discharge, satellite lesions, erythema with scaling, vesicles	Candidiasis, genital herpes, bacterial vaginosis, tinea, scabies	Vulvovaginal swabs (MC&S, NAAT if HSV suspected)
Neoplastic	Persistent plaque/nodule, ulceration not healing, pigmented lesion, warty growth	VIN, vulvar SCC, melanoma, Paget disease	Urgent biopsy; refer to gynaecological oncology
Functional / Pain	Normal or near-normal vulvar appearance; provoked pain on cotton-swab testing; hypertonic pelvic floor	Provoked vestibulodynia, vulvodynia, vaginismus	Pelvic floor physiotherapy referral; topical agents

💡

Clinical pearl: Overlapping domains are common. For example, a patient with longstanding lichen sclerosus (dermatological) may develop secondary candidiasis (infectious) or progress to differentiated-type VIN (neoplastic). Always consider more than one diagnosis and reassess if treatment response is suboptimal.

Lichen Sclerosus & Lichen Planus

Lichen Sclerosus (LS)

Lichen sclerosus is a chronic, relapsing inflammatory dermatosis with a predilection for anogenital skin. It is the most common vulvar dermatosis seen in Australian vulvar clinics. The aetiology is incompletely understood but involves an interplay of genetic susceptibility (HLA association), autoimmune dysregulation (associated with autoimmune thyroid disease, vitiligo, pernicious anaemia), and local factors (koebnerisation, hormonal milieu). Oestrogen deficiency is not causative but may unmask or exacerbate existing LS.

Clinical Features

Early/mild: Ivory-white, shiny papules and plaques on labia minora, clitoral hood, and perineum. Fine wrinkling ("cigarette-paper" appearance). Pruritus is the dominant symptom — often worse at night.
Moderate: Progressive resorption of labia minora, fusion of clitoral hood burying the clitoris, narrowing of the introitus, fissuring of the posterior fourchette.
Severe/advanced: Complete effacement of vulvar architecture ("figure-of-eight" pattern extending to perianal skin), porcelain-white atrophic skin, deep fissures, haemorrhagic blisters (rare), dyspareunia from introital stenosis.

🚨

Cancer risk: Vulvar squamous cell carcinoma develops in 4–5% of women with untreated or poorly managed LS. This risk persists even with treatment, necessitating lifelong surveillance at least annually. Any new nodule, indurated area, ulceration, or change in colour within a field of LS must be biopsied to exclude VIN or SCC.

First-Line Treatment

💊

Clobetasol Propionate 0.05%

Dermovate® · Emollia® · Topical corticosteroid (ultra-potent, Class I)

Adult dose Apply a thin layer to affected vulvar skin once nightly for 4 weeks → every second night for 4 weeks → twice weekly for 4 weeks (12-week induction course)

Maintenance 1–3 times weekly, titrated to the minimum frequency that maintains remission; lifelong in most patients

Application tip Apply using fingertip (pea-sized amount). Avoid mucosal surfaces. Use a mirror for self-application. Emollient (e.g., sorbolene) can be used as a daytime moisturiser alongside TCS.

Paediatric dose Same protocol as adults; used with caution. Supervised application by parent for prepubertal girls. Transition to less potent TCS (e.g., mometasone furoate 0.1%) once disease controlled.

Renal adjustment None required (minimal systemic absorption)

PBS status ✔ PBS Authority Required — for lichen sclerosus of vulva or penis

Second-Line and Adjunctive Therapies for LS

💊

Mometasone Furoate 0.1%

Elocon® · Potent topical corticosteroid (Class III)

Adult dose Apply once daily for maintenance when clobetasol achieves remission; also used as step-down in children

PBS status ✔ PBS General Benefit

💊

Tacrolimus Ointment 0.1%

Protopic® · Calcineurin inhibitor (steroid-sparing)

Adult dose Apply twice daily to affected area. Used as steroid-sparing agent for long-term maintenance or when TCS causes atrophy.

Note Initial burning is common and usually settles within 1–2 weeks. Not PBS-subsidised for vulvar use — private prescription.

PBS status ✘ Not PBS for vulvar LS (PBS-listed for atopic dermatitis only)

💊

Topical Oestrogen (Estriol)

Ovestin® cream · Vagifem® pessary · Oestriol 0.1%

Adult dose Ovestin®: 0.5 mg estriol intravaginally nightly for 2 weeks, then twice weekly maintenance. Adjunctive for vulvar atrophy in postmenopausal women with LS.

Note Does not treat LS directly but improves tissue quality and reduces atrophy-related symptoms. Can be used alongside clobetasol.

PBS status ✔ PBS General Benefit

Lichen Planus (LP)

Vulvar lichen planus is a less common but often more symptomatic and destructive condition than LS. It affects the vulva, vagina, or both. Three clinical subtypes are recognised: erosive (most common vulvar subtype), papulosquamous, and hypertrophic. Erosive LP is particularly problematic because it may cause adhesions, vaginal stenosis, and obliteration of the vestibule. LP is associated with hepatitis C virus infection in some populations (screening recommended).

Clinical Features

Papulosquamous LP

Mild

Violaceous flat-topped papules with Wickham's striae on labia majora. May be asymptomatic or mildly pruritic. Often associated with oral lichen planus (lichen planus mucosae).

Setting: GP with dermatology support

Erosive LP

Moderate

Bright red erosions of vestibule and vagina with fibrinoid exudate. Desquamative vaginitis with bloody discharge. Burning, stinging, and dyspareunia are prominent. Introital and vaginal adhesions may begin.

Setting: Vulvar specialist / dermatologist

Advanced Erosive LP

Severe

Complete vaginal obliteration from adhesions, loss of labia minora, clitoral burial, severe dyspareunia or inability to have penetrative intercourse. Risk of vaginal SCC (lower than LS-SCC but documented).

Setting: Vulvar specialist / gynaecologist with vulvar expertise

Management of Lichen Planus

💊

Clobetasol Propionate 0.05% (Erosive LP)

Dermovate® · Topical corticosteroid (ultra-potent)

Adult dose Apply once daily to erosions for 4–6 weeks, taper to twice weekly. Apply to vaginal erosions using a finger cot or vaginal applicator.

PBS status ✔ PBS Authority Required

💊

Pimecrolimus Cream 1%

Elidel® · Calcineurin inhibitor

Adult dose Apply twice daily to vulvar erosions. Used as steroid-sparing alternative or in combination for refractory disease.

PBS status ✘ Not PBS for vulvar LP — private prescription

💊

Hydroxychloroquine

Plaquenil® · Immunosuppressant / anti-inflammatory

Adult dose 200 mg orally twice daily. Used for refractory erosive LP under specialist guidance.

Monitoring Baseline and annual ophthalmological review (retinal toxicity screening) after 5 years of use; baseline FBC, LFT.

Renal adjustment Use with caution if eGFR <30 mL/min/1.73 m²

PBS status ✔ PBS Authority Required — for connective tissue diseases / inflammatory conditions

⚠️

Vaginal stenosis prevention: In erosive LP with vaginal involvement, regular use of vaginal dilators (graded sizes) and topical corticosteroids can prevent adhesion formation. Early specialist referral is critical — once vaginal obliteration occurs, surgical management (vaginoplasty) may be required.

Vulvar Intraepithelial Neoplasia (VIN) & Candidiasis

Vulvar Intraepithelial Neoplasia (VIN)

VIN is a pre-malignant condition of the vulvar epithelium, classified into two distinct clinicopathological entities with different aetiologies, demographics, and malignant potential:

Feature	Usual-Type VIN (uVIN)	Differentiated-Type VIN (dVIN)
Aetiology	HPV (types 16, 18, 33)	Non-HPV; associated with chronic LS, lichen planus, TP53 mutations
Age group	Premenopausal women (30–50 years)	Postmenopausal women (60–80 years)
Clinical appearance	Multifocal, pigmented or white, warty/flat papules, often perineal and perianal	Unifocal, often subtle — a pale, sharply demarcated plaque within a field of LS; may be mistaken for unchanged LS
Malignant progression	~5–10% over 10 years (slower)	~30–50% — much higher and faster progression to SCC
HPV vaccination impact	Reduced incidence expected in vaccinated cohorts (NIP: Gardasil 9® from age 12)	Not prevented by HPV vaccination

Diagnosis and Management of VIN

Biopsy is mandatory: Any persistent vulvar lesion, particularly within a field of LS, that does not respond to standard anti-inflammatory treatment must be biopsied (punch biopsy or incisional biopsy under local anaesthesia).
Staging: Referral to gynaecological oncology for confirmed VIN. Colposcopy of the vulva (vulvoscopy) and mapping biopsies are performed by the specialist.
Treatment of uVIN: Local excision, laser ablation, or topical imiquimod (Aldara® 5% cream, applied 3× weekly for 12–16 weeks — off-label for vulvar use in Australia but used under specialist supervision).
Treatment of dVIN: Wide local excision with adequate margins (≥1 cm) is the preferred approach given high progression risk. Simple vulvectomy may be required for extensive disease.
Post-treatment surveillance: Lifelong follow-up every 6–12 months with vulvar examination. Recurrence rates are 15–40% for uVIN.

💊

Imiquimod 5% Cream

Aldara® · Immune response modifier

Adult dose Apply to VIN lesion 3× weekly (e.g., Mon/Wed/Fri) for 12–16 weeks. Wash off after 6–10 hours. Off-label for VIN in Australia — use under specialist supervision.

Side effects Local erythema, erosion, pain, flu-like symptoms. Treatment-limiting in ~20% of patients.

PBS status ✔ PBS General Benefit — listed for genital warts; VIN use is off-label

Vulvovaginal Candidiasis (VVC)

Vulvovaginal candidiasis is the second most common cause of vaginitis in Australian women (after bacterial vaginosis). Most episodes are uncomplicated and readily treated. However, recurrent VVC (≥4 symptomatic episodes per year) and non-albicans candidiasis require prolonged and alternative treatment strategies.

Classification of VVC

Uncomplicated VVC

Mild to Moderate

Sporadic or infrequent (≤3 episodes/year). Caused by C. albicans. Mild-to-moderate symptoms (pruritus, white "cottage cheese" discharge, dyspareunia). Non-pregnant, non-immunocompromised.

Setting: GP — empirical or swab-guided treatment

Complicated VVC

Moderate

Recurrent VVC (≥4/year), severe symptoms, non-albicans species, or occurring in pregnancy, diabetes, or immunosuppression. Requires longer treatment courses and investigation.

Setting: GP with specialist input if recurrent

Refractory VVC

Severe

Non-albicans species (especially C. glabrata) failing standard azole therapy. May require boric acid vaginal suppositories or specialist-guided combination therapy.

Setting: Vulvar specialist / infectious diseases

Treatment of VVC

💊

Fluconazole

Diflucan® · Dizole® · Triazole antifungal

Uncomplicated VVC 150 mg orally as a single dose

Recurrent VVC induction 150 mg orally every 72 hours for 3 doses (induction), then 150 mg once weekly for 6 months (maintenance)

Paediatric dose ≥12 years: 150 mg single dose (uncomplicated). <12 years: 3–6 mg/kg single dose.

Renal adjustment Reduce dose by 50% if eGFR <50 mL/min/1.73 m²

Hepatic adjustment Use with caution; hepatotoxicity risk with prolonged courses. Monitor LFTs if >14 days of therapy.

PBS status ✔ PBS General Benefit

💊

Clotrimazole 1% or 2% Vaginal Cream

Canesten® · Imidazole antifungal (topical)

Adult dose 1% cream: 5 g intravaginally at night for 6 nights. 2% cream: 5 g intravaginally at night for 3 nights. Also apply to vulval skin BD for symptomatic relief.

Pregnancy Preferred topical agent in pregnancy. Avoid oral azoles in first trimester.

PBS status ✔ PBS General Benefit (also available OTC)

💊

Boric Acid 600 mg Vaginal Suppositories

Compounded · Non-azole antifungal

Adult dose 600 mg vaginally at night for 14 days. Used for non-albicans VVC (especially C. glabrata) refractory to fluconazole.

Note Must be compounded by a pharmacist (not commercially available as pessary). Toxic if ingested. Advise patient to avoid oral intake.

PBS status ✘ Not PBS — compounded medication, private cost

💡

Recurrent VVC workup: Confirm diagnosis with vulvovaginal swab (MC&S with speciation). Screen for diabetes (HbA1c, fasting glucose) and consider HIV testing. Review medications (oestrogen-containing contraceptives, antibiotics). If non-albicans species isolated, fluconazole is less effective — use topical clotrimazole or boric acid.

Pruritus Vulvae & Provoked Vestibulodynia

Pruritus Vulvae

Pruritus vulvae (chronic vulvar itching) is a symptom, not a diagnosis, and it is the most common presenting complaint in vulvar clinics. A structured differential diagnosis is essential, as treatment directed at the wrong cause is not only ineffective but may worsen the condition (e.g., prolonged topical antifungal use for LS causing irritant dermatitis).

Differential Diagnosis of Chronic Pruritus Vulvae

Category	Condition	Key Features	Initial Approach
Infectious	Candidiasis	Acute or recurrent, erythema, satellite lesions, white discharge	Vulvovaginal swab; empirical fluconazole 150 mg
Dermatological	Lichen sclerosus	White plaques, cigarette-paper skin, architecture loss	Clobetasol 0.05%; biopsy if diagnosis uncertain
Dermatological	Contact dermatitis	Erythema, oedema, excoriation; related to products (soap, wipes, laundry detergent, panty liners)	Eliminate all irritants; soap-free wash (e.g., Dermeze®); short course of moderate TCS
Dermatological	Lichen simplex chronicus	Thickened, leathery (lichenified) skin from chronic scratching/itch-scratch cycle	Break itch-scratch cycle: potent TCS + sedating antihistamine at night (e.g., promethazine 10–25 mg)
Dermatological	Psoriasis	Well-demarcated, salmon-pink plaques with fine scale; often bilateral. Check for scalp, elbow, knee involvement.	Moderate TCS; dermatology referral if widespread
Atrophic	Vulvovaginal atrophy	Pale, thin, dry vulvar/vaginal mucosa. Postmenopausal. Burning more than itch.	Topical oestrogen (Ovestin®); non-hormonal moisturiser (e.g., RepHresh®)
Neoplastic	VIN / vulvar malignancy	Persistent lesion not responding to treatment, focal change within LS	Biopsy; urgent gynaecology referral
Systemic	Diabetes mellitus, iron deficiency, thyroid disease	Generalised pruritus, recurrent candidiasis, no visible vulvar lesion	HbA1c, FBC, ferritin, TFTs

General Vulvar Care Advice (All Patients)

✅

Wash: Use warm water only or a soap-free wash (e.g., Dermeze®, QV Wash®). Avoid all soap, shower gel, bubble bath, and feminine hygiene products.
Dry: Pat dry gently; do not rub. Avoid talcum powder.
Clothing: Wear loose cotton underwear. Avoid synthetic fabrics, tight jeans, and panty liners where possible.
Moisturise: Apply a bland emollient (sorbolene with glycerine, Dermeze®, white soft paraffin/50:50) liberally to vulvar skin 2–3 times daily as a barrier moisturiser.
Avoid irritants: No bubble baths, fragranced products, wet wipes, douches, or vaginal deodorants.

Provoked Vestibulodynia (PVD)

Provoked vestibulodynia (formerly vulvar vestibulitis) is a chronic vulvar pain syndrome characterised by localised provoked pain at the vestibule upon touch or pressure, in the absence of visible pathology. It is the most common cause of provoked dyspareunia in premenopausal Australian women and is classified as a subset of vulvodynia under the ISSVD (International Society for the Study of Vulvovaginal Disease) 2015 terminology.

Aetiology and Contributing Factors

Peripheral sensitisation: Increased density of nociceptors and pro-inflammatory mediators in vestibular mucosa. May be triggered by recurrent infections (candidiasis, HPV), irritant exposure, or hormonal factors (oral contraceptive pill use, particularly low-oestrogen formulations).
Central sensitisation: Prolonged peripheral input leads to central nervous system amplification of pain. Women with PVD show altered pain processing on functional MRI.
Pelvic floor muscle dysfunction: Hypertonic, overactive pelvic floor muscles are found in 80–90% of women with PVD, contributing to pain and vaginismus.
Psychosocial factors: Anxiety, catastrophising, hypervigilance, relationship distress, and history of sexual trauma are common and must be addressed as part of a biopsychosocial management plan.

Diagnosis

Cotton-swab (Q-tip) test: Lightly touch the vestibule at 1, 4, 6, 8, and 11 o'clock positions. A positive test (pain ≥4/10 on NRS) at one or more sites, with normal vestibular appearance, confirms provoked vestibulodynia.
Vulvar appearance should be normal. If white patches, erosions, or other visible lesions are present, pursue dermatological/infectious diagnoses before attributing pain to PVD.
Pelvic floor assessment: Internal vaginal examination to assess for pelvic floor hypertonicity (tenderness on palpation of levator ani, inability to relax).

Multimodal Management of PVD

Evidence strongly supports a multidisciplinary, multimodal approach. Pharmacotherapy alone is insufficient.

Pelvic Floor Physiotherapy

First-line treatment. Internal and external manual therapy, biofeedback, down-training of hypertonic muscles, desensitisation exercises. Refer to a pelvic floor physiotherapist (available in most Australian capital cities and many regional centres). Typically 8–12 sessions.

Topical Agents

Lidocaine 5% ointment (Xylocaine®) applied to vestibule 15–30 minutes before intercourse as a barrier anaesthetic. Topical amitriptyline 2%/baclofen 2% (compounded) nightly to vestibule — reduces peripheral sensitisation.

Systemic Neuromodulators

Amitriptyline 10–25 mg nocte, titrate to 50–75 mg (or gabapentin 300 mg TDS, titrate to 600–900 mg TDS). These are off-label but commonly used in Australian vulvar pain practice.

Psychological Support

Cognitive-behavioural therapy (CBT), mindfulness-based stress reduction (MBSR), and sex therapy/couples therapy for relationship impact. Chronic pain psychology referral recommended for all patients.

Surgery (Vestibulectomy)

Modified vestibulectomy (excision of painful vestibular tissue) is reserved for patients failing 12–24 months of conservative therapy. Success rates 60–90%. Available at select Australian tertiary centres.

💊

Lidocaine 5% Ointment

Xylocaine® 5% · Local anaesthetic

Adult dose Apply a generous layer to vestibule 15–30 minutes before intercourse. Remove excess before intercourse if numbness of partner is a concern.

Also used Nightly application during desensitisation programmes.

PBS status ✔ PBS General Benefit

💊

Amitriptyline

Endep® · Triyclic antidepressant / neuromodulator

Adult dose Start 10 mg orally at night; titrate by 10 mg every 1–2 weeks to 25–75 mg nocte. Maximum 150 mg/day.

Side effects Drowsiness, dry mouth, constipation, weight gain. Take advantage of sedating effect by dosing at night.

Renal adjustment Use lower doses if eGFR <30 mL/min/1.73 m²

PBS status ✔ PBS General Benefit

💊

Gabapentin

Neurontin® · Gabahexal® · Anticonvulsant / neuromodulator

Adult dose Start 300 mg orally at night; titrate by 300 mg every 3–5 days to 300 mg TDS. Maximum 3,600 mg/day (in divided doses).

Side effects Dizziness, somnolence, peripheral oedema, weight gain

Renal adjustment Dose reduction required: eGFR 30–59: 200–700 mg/day; eGFR 15–29: 100–300 mg/day; eGFR <15: 100 mg alternate days

PBS status ✔ PBS General Benefit

Investigations

Investigation of vulvar disorders is guided by the clinical domain identified through the Vulvar Discomfort Diagnostic Model. The following table summarises key investigations, their availability in Australian primary care, and relevant MBS items.

Essential Vulvovaginal swab (MC&S with candida speciation) Available in all Australian pathology labs. MBS item 69316. Collect from posterior fornix and vulvar skin. Speciation is important for recurrent VVC (non-albicans species identification).

Essential Vulvar skin biopsy (punch or incisional) Available in most GP practices with procedural skills. Local anaesthesia (1–2% lignocaine). Send to pathology in formalin. MBS item 30071 (punch biopsy). Essential for any persistent, non-responsive, or atypical lesion.

Available HSV NAAT swab For suspected genital herpes — swab vesicle/ulcer base. MBS item 69327. Results in 1–3 days.

Available HbA1c / Fasting glucose Screen for diabetes in recurrent VVC and chronic pruritus. MBS item 66551 (HbA1c).

Available FBC, ferritin, TFTs To exclude iron deficiency and thyroid disease in chronic pruritus. MBS item 65070.

Available Hepatitis C serology Recommended in confirmed lichen planus (association with HCV). MBS item 69397.

Available HIV serology Consider in recurrent/refractory VVC with risk factors. MBS item 69390.

Available Autoimmune screen (ANA, anti-TPO, anti-TG) LS is associated with autoimmune thyroiditis, vitiligo, pernicious anaemia. Screen if clinical features suggest autoimmune comorbidity.

Referral Vulvoscopy (vulvar colposcopy) Performed by gynaecologist or vulvar specialist. Acetic acid application to highlight acetowhite changes (VIN). Mapping biopsies may be taken.

Specialist HPV genotyping (vulvar biopsy specimen) Performed on biopsy specimen by anatomical pathology. Distinguishes HPV-related (usual-type) from non-HPV (differentiated-type) VIN.

⚠️

Biopsy thresholds: Any vulvar lesion that does not respond to 4–6 weeks of appropriate empirical therapy, any new nodule or induration within a field of lichen sclerosus, any pigmented or ulcerated lesion, and any persistent erosions unresponsive to topical corticosteroids should be biopsied. Do not delay biopsy — delayed diagnosis of vulvar cancer remains a significant clinical risk.

Empirical Therapy & Directed Management

Quick Reference — First-Line Treatment by Diagnosis

Lichen sclerosus

Clobetasol 0.05% TCS

12-week induction → lifelong maintenance

Annual review ± biopsy of new lesions

Erosive lichen planus

Clobetasol 0.05% ± tacrolimus 0.1%

6–8 weeks induction → long-term taper

Vaginal dilators if vaginal involvement. Specialist co-management.

Uncomplicated VVC

Fluconazole 150 mg PO stat

Single dose

Alternative: clotrimazole 2% cream 3 nights. Topical preferred in pregnancy.

Recurrent VVC

Fluconazole 150 mg PO q72h × 3 → then weekly

Induction 9 days → maintenance 6 months

Confirm diagnosis with MC&S. Speciate. Screen for diabetes.

uVIN

Excision / imiquimod 5%

Imiquimod: 12–16 weeks

Specialist management. HPV vaccination counselling. Lifelong surveillance.

dVIN

Wide local excision

Surgical (single episode)

High-grade — urgent gynae-oncology referral. 30–50% SCC progression risk.

Provoked vestibulodynia

Pelvic floor physiotherapy + lidocaine 5%

8–12 physio sessions + ongoing

Add amitriptyline or gabapentin if pain persists. CBT/sex therapy as adjunct.

Contact dermatitis

Eliminate irritants; mometasone 0.1%

2–4 weeks TCS

Soap-free wash. Bland emollient. Identify and avoid trigger.

Lichen simplex chronicus

Clobetasol 0.05% + sedating antihistamine

2–4 weeks TCS; antihistamine at night

Break itch-scratch cycle. Emollient maintenance. Consider doxepin 5% cream.

Monitoring

Week 0

Initiate treatment. Confirm diagnosis. Provide vulvar care education. Arrange appropriate investigations (swabs, biopsy if indicated). Document baseline vulvar appearance (photography if patient consents, or detailed diagram).

Week 4–6

Review response. For LS: expect significant symptom improvement with clobetasol. For VVC: confirm resolution. For PVD: review pelvic floor physiotherapy progress. If poor response, reconsider diagnosis — biopsy if not already done.

Week 12

End of induction phase (LS, LP). Assess for remission. Transition to maintenance regimen. Review medication tolerability. Ensure ongoing emollient use.

6 months

LS/LP: Confirm maintenance regimen is effective. PVD: Reassess pain scores and sexual function. Recurrent VVC: Evaluate whether maintenance fluconazole can be ceased.

12 months and ongoing

LS: Minimum annual review — vulvar examination for architectural change, new lesions, or features suggestive of VIN/SCC. Ensure patient self-monitoring education. VIN: Per specialist protocol (usually 6-monthly). LP: Annual review with vaginal assessment for stenosis.

📋

Patient self-monitoring: Educate all patients with LS and LP to perform monthly self-examination using a hand mirror. They should report any new lump, bump, area of thickening, ulceration, bleeding, or change in colour promptly. Provide written information (e.g., Australasian Vulvovaginal Society patient leaflets).

Special Populations

🤰

Pregnancy

Candidiasis in pregnancy: Topical imidazoles (clotrimazole, miconazole) are preferred. Avoid oral fluconazole in the first trimester (associated with congenital malformations at high doses). Recurrent VVC in pregnancy: topical clotrimazole 2% twice weekly for maintenance.

Lichen sclerosus: May worsen during pregnancy due to hormonal changes and stretching. Continue emollients. Clobetasol can be used at lowest effective potency. Avoid prolonged high-potency TCS on perineal skin near term (risk of skin thinning and perineal tearing during delivery).

Provoked vestibulodynia: Pain may improve or worsen during pregnancy. Pelvic floor physiotherapy is safe and encouraged. Avoid systemic neuromodulators (amitriptyline, gabapentin) unless specialist advice — teratogenicity data limited.

Most vulvar conditions do not preclude vaginal delivery. Discuss birth plan with obstetric team.

👶

Paediatrics

Lichen sclerosus in prepubertal girls: Accounts for 70% of vulvar dermatoses in children. Presents with pruritus, constipation (from perianal fissuring), and white perineal skin. Clobetasol 0.05% is safe — use under parental supervision for 4–6 weeks, then step down to mometasone 0.1%. Most cases improve or resolve at puberty, but some persist.

Vulvovaginitis in children: Common before puberty due to oestrogen-poor vulvar epithelium. Most cases are non-specific (poor hygiene, irritants). Candidiasis is uncommon prepubertally — consider sexual abuse if diagnosed. Advise cotton underwear, soap-free washing, barrier cream (zinc oxide or petroleum jelly).

Candidiasis: Fluconazole dose: 3–6 mg/kg single dose (max 150 mg) for children ≥12 years. Clotrimazole 1% cream can be used topically in children of all ages.

Child protection considerations: Vulvar bleeding, bruising, or STIs in prepubertal children should prompt consideration of sexual abuse — follow mandatory reporting requirements in your state/territory.

👵

Elderly

Vulvar atrophy: Postmenopausal vulvar atrophy is extremely common and may coexist with LS, LP, or PVD. Topical oestrogen (Ovestin®) improves tissue quality and reduces symptoms of dryness, burning, and dyspareunia. It is safe to use alongside TCS.

Lichen sclerosus peak incidence: Highest incidence in postmenopausal women. Cancer risk increases with age — ensure annual examination and biopsy any suspicious change. Maintain TCS treatment long-term.

Vulvar cancer: Median age at diagnosis 70 years. Any persistent vulvar ulcer, nodule, or non-healing lesion in an older woman must be biopsied urgently. Referral to gynaecological oncology.

Medication review: Elderly women may be on multiple medications. Polypharmacy can contribute to vulvar symptoms (e.g., antibiotics → candidiasis; diuretics → vulvar dryness).

🫘

Renal Impairment

Fluconazole: Reduce dose by 50% if eGFR <50 mL/min/1.73 m². Topical antifungals (clotrimazole, miconazole) are preferred if renal impairment is significant.

Gabapentin: Significant renal dose adjustment required. eGFR 30–59: max 700 mg/day; eGFR 15–29: max 300 mg/day; eGFR <15: 100 mg alternate days.

Amitriptyline: Use lower starting dose (5–10 mg) in significant renal impairment. Monitor for excessive sedation and anticholinergic effects.

Topical corticosteroids for LS/LP: Minimal systemic absorption — no renal adjustment required.

🫀

Hepatic Impairment

Fluconazole: Use with caution; hepatotoxicity risk. Monitor LFTs with prolonged courses (>14 days). Topical agents preferred in significant hepatic disease.

Hydroxychloroquine (for LP): Avoid in severe hepatic impairment. Hepatotoxicity is rare but documented.

Topical corticosteroids: Safe — no hepatic adjustment.

Screen for hepatitis C in women with lichen planus — HCV–LP association is well established.

🛡️

Immunocompromised

Recurrent VVC: Very common in immunocompromised women (HIV, transplant, biologics, chemotherapy). May require prolonged induction fluconazole (14–21 days) and indefinite maintenance. Non-albicans species more common — always speciate.

HSV reactivation: Vulvar herpes simplex may present atypically and be more severe. Consider suppressive aciclovir (400 mg PO BD) after initial episode.

VIN and vulvar cancer: HIV-positive women have 20–50× increased risk of VIN due to HPV co-infection. Regular vulvar examination should be part of routine HIV care. HPV vaccination is recommended (funded under NIP for eligible age groups).

Coordinate care with infectious diseases or immunology specialist. Drug interactions with antiretrovirals may affect fluconazole dosing (CYP3A4 interactions).

Aboriginal and Torres Strait Islander Health

Aboriginal and Torres Strait Islander Health Considerations

Vulvar disorders in Aboriginal and Torres Strait Islander women present unique challenges related to healthcare access, cultural considerations, and the epidemiological profile of skin disease in Indigenous communities. Health professionals must approach these conditions with cultural sensitivity, an awareness of historical and ongoing barriers to care, and a commitment to trauma-informed practice.

Access to specialist care

Many Aboriginal and Torres Strait Islander women, particularly those in remote and very remote communities, have limited access to gynaecological, dermatological, and vulvar specialist services. Telehealth consultations with state-based vulvar clinics (e.g., Royal Women's Hospital Melbourne, Women's and Children's Hospital Adelaide, Royal Hospital for Women Sydney) can bridge some gaps. The Specialist Outreach Program (SOP) funded by the Australian Government may facilitate visiting specialist clinics.

Cultural sensitivity in examination

Vulvar examination is a highly sensitive matter. Ensure the presence of a female health practitioner where possible. Offer the option of a female Aboriginal and/or Torres Strait Islander health worker or family member as a support person. Use clear, respectful language and explain each step of the examination. Recognise that "shame" and cultural taboos around genital examination may delay presentation — create a safe, non-judgemental environment.

Skin disease burden

Aboriginal and Torres Strait Islander Australians experience significantly higher rates of skin disease, including scabies, tinea, and bacterial skin infections, compared with the non-Indigenous population. These conditions may coexist with or mask vulvar dermatoses. Chronic skin conditions in remote communities (up to 50% prevalence of skin infections in some communities) require concurrent management.

Vulvar cancer and VIN

Aboriginal and Torres Strait Islander women have higher rates of vulvar cancer diagnosed at advanced stages due to delayed presentation and limited screening access. HPV vaccination coverage in Indigenous communities has improved but remains lower than the national average in some jurisdictions. Ensure all eligible young people receive funded Gardasil 9® vaccination under the National Immunisation Program.

Medication access and PBS

Aboriginal and Torres Strait Islander patients registered with a health service and holding a Medicare card may be eligible for Closing the Gap PBS Co-Payment Program medications — this reduces out-of-pocket costs for Authority Required medications including clobetasol propionate and fluconazole. Health practitioners should ensure correct "CTG" annotation on PBS prescriptions.

Social determinants

Overcrowded housing, limited access to clean water, and reduced availability of personal hygiene products contribute to vulvar morbidity in remote communities. Advocacy for improved housing, water supply, and availability of soap-free washes and emollients (e.g., through community health programs) is essential. Bulk-supplied bland emollients (sorbolene, white soft paraffin) should be available at community health centres.

📞

Support and referral pathways: Contact your state/territory Aboriginal health service or the Australian Indigenous HealthInfoNet (healthinfonet.ecu.edu.au) for culturally appropriate resources. The Australasian Vulvovaginal Society provides patient information in plain English. Consider using visual aids and locally adapted health education materials for patient education about vulvar self-care and self-monitoring.

📚 References

1. Lee A, Bradford J, Fischer G. Long-term management of adult vulvar lichen sclerosus: a prospective cohort study of 507 women. JAMA Dermatology. 2015;151(10):1061–1067.
2. Goldstein AT, Pukall CF, Brown C, Bergeron S, Stein A, Kellogg-Spadt S. Vulvodynia: assessment and treatment. J Sex Med. 2016;13(4):572–590.
3. van der Meijden WI, Boffa M, Ter Harmsel WA, et al. 2021 European guideline for the management of vulval conditions. J Eur Acad Dermatol Venereol. 2022;36(7):952–972.
4. Australian Institute of Health and Welfare (AIHW). Cancer data in Australia. Canberra: AIHW; 2023. Available from: aihw.gov.au.
5. Bornstein J, Bogliatto F, Haefner HK, et al. The 2015 International Society for the Study of Vulvovaginal Disease (ISSVD) terminology of vulvar squamous intraepithelial lesions. J Low Genit Tract Dis. 2016;20(1):11–14.
6. Bradford J, Fischer G. Management of vulvovaginal lichen planus: a new approach. J Low Genit Tract Dis. 2013;17(1):20–25.
7. Dennerstein G, Scurry J, Garland S, et al. Vulvar intraepithelial neoplasia: clinical review. Genitourin Med. 2017;93(3):171–178.
8. Royal Australian College of General Practitioners (RACGP). Guidelines for preventive activities in general practice (Red Book). 9th ed. Melbourne: RACGP; 2018.
9. Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM). Australian STI management guidelines for use in primary care. Sydney: ASHM; 2023. Available from: sti.guidelines.org.au.
10. Australian Indigenous HealthInfoNet. Overview of Aboriginal and Torres Strait Islander health status 2023. Perth: Edith Cowan University; 2024. Available from: healthinfonet.ecu.edu.au.
11. Pukall CF, Goldstein AT, Bergeron S, et al. Vulvodynia: definition, prevalence, impact, and pathophysiological factors. J Sex Med. 2016;13(3):291–304.
12. Bagis T, Boffa MJ, Lewis FM. The burden of vulvar pain: a population-based cross-sectional survey in the UK. Br J Dermatol. 2022;186(5):853–862.
13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated). Relevant to vulvar research and informed consent in examination.
14. Sobel JD, Sobel R. Current treatment options for vulvovaginal candidiasis caused by non-albicans Candida species. Expert Opin Pharmacother. 2021;22(7):863–873.
15. Department of Health and Aged Care, Australian Government. National Immunisation Program Schedule. Canberra: Commonwealth of Australia; 2024. Available from: health.gov.au.

for PBS scripts. Utilise ACCHS pharmacies and Remote Area Aboriginal Health Worker programs for medication supply in remote areas. Avoid initiating benzodiazepines; support holistic pain management including community-based exercise programs.

Preventive health

Promote bone health: encourage vitamin D supplementation (1000 IU daily in deficient individuals), smoking cessation support, reduction of alcohol intake, and weight-bearing exercise. MBS Item 715 health checks provide a structured opportunity to assess bone health, screen for osteoporosis risk factors, and discuss musculoskeletal health in a culturally safe context.

Quick Reference: Differential Diagnosis at a Glance

Costovertebral dysfunction

Paracetamol ± NSAID; manual therapy

2–6 weeks

Provocable on palpation; no red flags

Thoracic compression fracture

Paracetamol; ± calcitonin; DXA + osteoporosis Rx

6–12 weeks healing

Elderly; osteoporosis; acute onset

ACS (posterior MI)

Aspirin 300 mg, GTN, heparin; urgent PCI

Time-critical

ECG, troponin; CV risk factors

Aortic dissection

IV labetalol; urgent CT aortogram; surgery (Type A)

Time-critical

Tearing pain; BP differential >20 mmHg

Vertebral osteomyelitis

IV antibiotics (vancomycin + ceftriaxone initially); ID consult

6 weeks IV antibiotics

Fever, elevated CRP, IV drug use

Biliary colic / cholecystitis

Paracetamol ± morphine; lap cholecystectomy

Surgical within 72 h (cholecystitis)

RUQ/infrascapular; post-prandial; RUQ US

📚 References

1. Briggs AM, Smith AJ, Straker LM, Bragge P. Thoracic spine pain in the general population: prevalence, incidence and associated factors in children, adolescents and adults. A systematic review. BMC Musculoskelet Disord. 2009;10:77.
2. National Health and Medical Research Council (NHMRC). Evidence-based management of acute musculoskeletal pain. Canberra: NHMRC; 2003 (updated 2020).
3. Australian Institute of Health and Welfare (AIHW). Aboriginal and Torres Strait Islander Health Performance Framework: Summary report 2023. Canberra: AIHW; 2023.
4. Deyo RA, Rainville J, Kent DL. What can the history and physical examination tell us about low back pain? JAMA. 1992;268(6):760–765.
5. Stochkendahl MJ, Kjaer P, Hartvigsen J, et al. National Clinical Guidelines for non-surgical treatment of patients with recent onset low back pain or lumbar radiculopathy. Europ Spine J. 2018;27(1):60–75.
6. Erwin WM, Jackson PC, Homonko DA. Innervation of the human costovertebral joint: implications for clinical back pain syndromes. J Manipulative Physiol Ther. 2000;23(6):395–403.
7. Royal Australian College of General Practitioners (RACGP). Guidelines for preventive activities in general practice. 9th edn. Melbourne: RACGP; 2018 (updated 2023).
8. Hirsch JA, Singh V, Falco FJE, et al. Thoracic facet joint interventions. Pain Physician. 2016;19(4):E581–E593.
9. Erwin WM, Jackson PC. The costovertebral joint: anatomy, biomechanics, and clinical significance in thoracic back pain syndromes. J Can Chiropr Assoc. 2003;47(2):112–120.
10. Strayer RJ, Gunnerson JM, Brown LH, et al. Aortic dissection: clinical features, diagnosis, and management. Aust Crit Care. 2019;32(2):144–153.
11. Ombregt L. A system of orthopaedic medicine. 3rd edn. Edinburgh: Churchill Livingstone Elsevier; 2013. Chapter 18: Thoracic spine.
12. Lin CC, Chen KH, Li DM, et al. Characteristics and outcomes of patients presenting with thoracic back pain to the emergency department. Emerg Med Australas. 2020;32(5):805–811.

for PBS-listed medicines at participating pharmacies.

Cultural safety

Engagement with Aboriginal Community Controlled Health Organisations (ACCHOs) is essential. Cultural safety training for non-Indigenous clinicians, use of Aboriginal Health Workers and Liaison Officers, and incorporation of traditional healing practices alongside Western medicine improve treatment adherence and outcomes. Avoidance of eye contact, respect for gender-sensitive examination practices, and understanding of sorry business protocols are critical elements of culturally safe care.

Medication adherence

Complex DMARD regimens with frequent monitoring requirements present adherence challenges. Long-acting depot injections (e.g., methotrexate SC) may improve adherence compared to oral regimens. Community pharmacy partnerships through the Indigenous Pharmacy Programmes improve medication management.

Specific conditions

Rheumatic heart disease (RHD) requires secondary prophylaxis with benzathine penicillin G (BPG) 1.2 MU IM every 3–4 weeks for a minimum of 10 years or until age 21 (whichever is longer). RHD registers (e.g., NT RHD Register) facilitate recall and follow-up. The Australian RHD Endgame Strategy targets elimination by 2031.

Referral pathways

Referral through ACCHOs and Aboriginal Hospital Liaison Officers (AHLOs) improves engagement. The Specialist Outreach Assistance Programme provides funded specialist visits to remote communities. NT, WA, and QLD have specific rheumatology outreach programmes targeting Indigenous communities.

📚 References

1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).

for PBS-listed medicines at participating pharmacies.

Cultural safety

Medication adherence

Specific conditions

Referral pathways

📚 References

1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).